A Phase II, Active-Controlled, Multicenter Study Comparing The Efficacy & Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling vs. Platinum Based Chemotherapy in Patients with Cancer of Unknown Primary Site who Have Received Three Cycles of Platinum Doublet Chemotherapy, MX39795 (CUPISCO)

Carboplatin/Paclitaxel oder Cisplatin/Gemcitabin

Status: Rekrutierung beendet

Klinische Settings

Beteiligte

Identifier

Links

Kontakt